Chemotherapy protocols and incidence of oral mucositis. An integrative review

Protocolos quimioterápicos e incidência de mucosite bucal. Revisão integrativa

Marina Curra1, Luiz Alberto Valente Soares Junior2, Manoela Domingues Martins3, Paulo Sérgio da Silva Santos4

1 Universidade de Caxias do Sul, Caxias do Sul, RS, Brazil.
2 Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.
3 Faculdade de Odontologia, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
4 Faculdade de Odontologia de Bauru, Universidade de São Paulo, Bauru, SP, Brazil.

DOI: 10.1590/S1679-45082018RW4007

ABSTRACT

This review aimed to analyze the scientific production on severity of oral mucositis as an adverse effect of chemotherapy. To this end, we performed a search at PubMed databases combining the keywords “oral mucositis” and “chemotherapy protocol”. To describe the investigation, the following variables were considered: journal, year/place, study design, sample, protocol used and incidence of oral mucositis. A total of 547 articles were retrieved, of which 26 were selected. Out of these 26, only 2 reported severity of oral mucositis; the others only reported the presence of the condition. Protocols for treating different types of carcinoma were evaluated in 16 (61.53%) studies, for hematological malignancies in 6 (23.07%), and for hematopoietic stem cell transplantation in 4 (15.4%). Protocols for hematopoietic stem cell transplantation entail a high risk for oral mucositis, just as chemotherapy with cytarabine and high-dose 5-fluorouracil, alkylating agents and platinum-based compounds. To provide the best prevention and treatment for oral mucositis, it is essential to know the chemotherapy protocols used and their effects on the oral cavity.

Keywords: Stomatitis/drug therapy; Stomatitis/chemically induced; Toxicity

INTRODUCTION

The primary objective of oncological treatments, such as chemotherapy, is to destroy cancer cells. However, most chemotherapeutic agents do not act
selectively, i.e. they act on both malignant and normal cells, particularly fast-growing cells, such as gastrointestinal, capillary, and immune cells.\(^{(1-3)}\) The toxicity of chemotherapeutic agents is known to be associated with the mode of action, dose and interaction between different agents in a given protocol.\(^{(4,5)}\)

Oral mucositis (OM) is an important adverse effect seen in cancer patients on chemotherapy and/or radiation therapy for the head and neck.\(^{(2,6,7)}\) This condition presents clinically as erosive and/or ulcerative lesions that can cause mild to severe pain.\(^{(1,2,8)}\) These lesions usually lead to a significant decrease in quality of life, since they can prolong hospital stay, affect the nutritional status of the patient, increase the risk of infections, and increase the prescription of opioids.\(^{(9-11)}\)

For these reasons, treatment of OM is extremely necessary, with the aim of relieving symptoms, accelerating tissue repair and controlling infections of oral origin. Currently, efforts are focused on preventing OM. The Mucositis Study Group of the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology (MASCC/ISOO) has published guidelines\(^{(12)}\) to orient the clinical practice for prevention/treatment of this condition. In these guidelines, preventive measures for OM are described without specification of the chemotherapy protocol used.

The known association between toxicity and the chemotherapy protocol used may guide selection of the right prevention methods to control OM in high-risk populations.

**OBJECTIVE**

To review the scientific production on severity of oral mucositis as an adverse effect of different chemotherapy protocols.

**METHODS**

An integrative review with data gathered from multiple articles to assist in understanding how different chemotherapy protocols can trigger mild or severe degrees of OM. In the field of health, the amount of information is ever growing, and evidence-based practice has become a must. In this way, the methodology of integrative reviews aims to synthesize knowledge to be incorporated in the practice by identifying independent studies on the same subject and analyzing their results.

This review was based on a search at PubMed databases. The search was started and completed in May 2016. Studies published in English, Spanish or Portuguese were selected for analysis. There were no restrictions regarding the year of publication and the studies retrieved were published before May 2016. After the search, the articles were selected according to their inclusion and exclusion criteria. The search strategy was based on a combination of the keywords “oral mucositis” and “chemotherapy protocols”.

The inclusion criteria were original articles with open access to the full text, whose study subjects were patients diagnosed with OM after chemotherapy. Case reports, clinical trials, and literature reviews were excluded, as well as articles that did not describe the outcomes of the chemotherapy-associated OM.

**RESULTS**

Using the keywords of choice, 547 articles were retrieved. Of those, 325 articles were excluded by the title, 173 by the abstract and 23 by the full text, which left us with 26 articles.

The 26 articles selected were in English, published between 1987 and 2015, and the largest number of studies was from the last 5 years (\(n=8\)). All articles were original, including 24 prospective and only two retrospective studies. Of the 26 articles, only two aimed to evaluate severity of OM triggered by a given chemotherapy protocol. The other 24 studies focused on treatment efficacy and safety, and just reported the incidence of OM.

Table 1 displays the sample of each study, the chemotherapy protocol used and the severity of OM.
### Table 1. Distribution of protocols used in each study and severity of oral mucositis

| Article                        | Sample   | Protocol                                                                 | Severity of mucositis |
|-------------------------------|----------|--------------------------------------------------------------------------|-----------------------|
| Chibaudel et al.(13)          | 42 patients | Cetuximab (IV) D1, 8 and 15 Cisplatin D1, 8 and 15 5-FU 750mg/m² D1-5 | G0 = 27 (65.8%)       |
|                               | Mean age: 56 years; Oropharyngeal carcinoma | Protocol 1 - FOLFOX 4 - Oxaliplatin 85mg/m² (IV) D1 5-FU 400mg/m² bolus + 600mg/m² continuous D1 and 2 - Leucovorin 200mg/m² D1 and 2 Protocol 2 - FOLFOX 6 - Oxaliplatin 100mg/m² (IV) D1 - 5-FU 400mg/m² bolus + 2,400mg/m² continuous D1 and 2 - Leucovorin 400mg/m² D1 and 2 Protocol 3 - mFOLFOX 6 - Oxaliplatin 100mg/m² (IV) D1 - 5-FU 2,000mg/m² continuous D1 and 2 - Leucovorin 100mg/m² D1 and 2 Protocol 4 - FOLFOX 7 - Oxaliplatin 130mg/m² (IV) D1 - 5-FU 2,400mg/m² continuous D1 and 2 - Leucovorin 400mg/m² D1 and 2 | G1 = 9 (12.2%) G2 = 4 (9.8%) G3 = 5 (12.2%) G4 = 0 |
| Bano et al.(14)               | 38 patients | Protocol 1 - FOLFOX 4 - Oxaliplatin 85mg/m² (IV) D1 5-FU 400mg/m² bolus + 600mg/m² continuous D1 and 2 - Leucovorin 200mg/m² D1 and 2 Protocol 2 - FOLFOX 6 - Oxaliplatin 100mg/m² (IV) D1 - 5-FU 400mg/m² bolus + 2,400mg/m² continuous D1 and 2 - Leucovorin 400mg/m² D1 and 2 Protocol 3 - mFOLFOX 6 - Oxaliplatin 100mg/m² (IV) D1 - 5-FU 2,000mg/m² continuous D1 and 2 - Leucovorin 100mg/m² D1 and 2 Protocol 4 - FOLFOX 7 - Oxaliplatin 130mg/m² (IV) D1 - 5-FU 2,400mg/m² continuous D1 and 2 - Leucovorin 400mg/m² D1 and 2 | Protocol 1 - G0 = 24% G1 and 2 = 66% G3 and 4 = 11% |
|                               | Mean age: 61 years; Colorectal carcinoma | Protocol 2 = 13 patients Protocol 3 = 5 patients Protocol 4 = 8 patients | Protocol 2 - G0 = 38% G1 and 2 = 56% G3 and 4 = 6% |
|                               | Protocol 1 = 13 patients | Protocol 3 = 5 patients | Protocol 4 = 8 patients | Protocol 3 - G0 = 21% G1 and 2 = 79% G3 and 4 = 0 |
| Wang et al.(15)               | 65 patients | Cisplatin 50mg/m² (IV) D1 Tegafur 800mg (PO) D1-14 Leucovorin 60mg (PO) D1-14 | G0 = 3.1% G1 = 1.5% G2 = 15.4% G3 = 73.8% G4 = 6.2% |
|                               | Mean age: not informed; Oropharyngeal and hypopharyngeal carcinoma | Protocol 1 - Everolimus | G0 = 0 G1 = 10 (29.4%) G2 = 14 (41.2%) G3 = 9 (26.5%) G4 = 1 (2.9%) |
| Aapro et al.(16)              | 1. Renal carcinoma = 274 patients | Everolimus | 1. G1-G4 = 44% 2. G1-G4 = 64% 3. G1-G4 = 59% |
|                               | 2. Neuroendocrine tumors = 204 patients | Everolimus | 2. G1-G4 = 64% 3. G1-G4 = 59% |
|                               | 3. Breast cancer = 482 patients | Everolimus | 3. G1-G4 = 59% |
|                               | Mean age: not informed | Everolimus | 3. G1-G4 = 59% |
| Tao et al.(17)                | 34 patients | Cisplatin 5-FU Radiation therapy | G0 = 0 G1 = 10 (29.4%) G2 = 14 (41.2%) G3 = 9 (26.5%) G4 = 1 (2.9%) |
|                               | Mean age: 16 years; Nasopharyngeal carcinoma | Cisplatin 5-FU Radiation therapy | G0 = 0 G1 = 2 (4%) G3 and 4 = 0 G4 = 0 |
| Lin et al.(18)                | 134 patients | 3 cycles 5-FU 750mg/m² D1-5 Radiation therapy | 1. G0 = 2 2. G0 = 58 3. G0 = 0 1. G0 = 92 2. G0 = 58 3. G0 = 0 |
|                               | Mean age: 42 years; Nasopharyngeal carcinoma | 3 cycles 5-FU 750mg/m² D1-5 Radiation therapy | 1. G0 = 92 2. G0 = 58 3. G0 = 0 |
|                               | Mean age: 42 years; Nasopharyngeal carcinoma | 3 cycles 5-FU 750mg/m² D1-5 Radiation therapy | 1. G0 = 92 2. G0 = 58 3. G0 = 0 |
| Iwata et al.(19)              | 51 patients | Lapatinib 1,250mg qd Capecitabine 1,000mg/m² bid | G0 = 30 (59%) G1 = 21 (41%) G2 = 0 G3 = 0 G4 = 0 |
|                               | Mean age: 55 years; Breast cancer | Lapatinib 1,250mg qd Capecitabine 1,000mg/m² bid | G0 = 30 (59%) G1 = 21 (41%) G2 = 0 G3 = 0 G4 = 0 |
| Palappallil et al.(20)        | 1. 50 patients | 1. FAC 5-FU 500mg/m² Doxorubicin 50mg/m² Cyclophosphamide 500mg/m² 2. AC-P Doxorubicin 60mg/m² Cyclophosphamide 600mg/m² Paclitaxel 175mg/m² | 1. G1-G4 = 45 (90%) 2. G1-G4 = 2 (4%) |
|                               | Mean age: 45 (20-70) years; Breast cancer | 1. FAC 5-FU 500mg/m² Doxorubicin 50mg/m² Cyclophosphamide 500mg/m² 2. AC-P Doxorubicin 60mg/m² Cyclophosphamide 600mg/m² Paclitaxel 175mg/m² | 1. G1-G4 = 45 (90%) 2. G1-G4 = 2 (4%) |

*continue...*
Table 1. Distribution of protocols used in each study and severity of oral mucositis

| Article                        | Sample                  | Protocol                          | Severity of mucositis   |
|--------------------------------|-------------------------|-----------------------------------|-------------------------|
| Baird et al.,(21)              | 1. 200 patients         | 1. CAPOX 2000                     | 1. G1 = 22 (11%)        |
|                                |                         | Capectabine 2,000mg/m² D1-14      | G2 = 5 (2.5%)           |
|                                |                         | Oxaliplatin 130mg/m² D1           | G3 = 0 (0%)             |
|                                |                         | 2. CAPOX 1.700                    | G4 = 0 (0%)             |
|                                | 2. 200 patients         | Capectabine 1,700mg/m² D1-14      | 2. G1 = 22 (11%)        |
|                                |                         | Oxaliplatin 130mg/m² D1           | G2 = 5 (2.5%)           |
|                                |                         | Cetuximab                         | G3 = 2 (1%)             |
|                                |                         |                                   | G4 = 0 (0%)             |
| Lee et al.,(22)                | 32 patients             | Capectabine 2,000mg/m² D1-14      | G1-G2 = 4 (12.9%)       |
|                                |                         | Cisplatin 60mg/m² D1              | G3-G4 = 1 (3.2%)        |
| Abromowitch et al.,(23)        | 1. 85 patients          | 1. Induction                      | 1. Induction            |
|                                |                         | Vincristine 1.5mg/m² D0, 7 and 14 | G1-G4 = 0 (0%)          |
|                                |                         | Daunorubicin 60mg/m² D1 and 2     | 2. Consolidation        |
|                                | 3.1. 76 patients        | Cyclophosphamide 1,200mg/m² D0    | G1-G4 = 5 (6.1%)        |
|                                | 3.2. 73 patients        | L-Asparaginase                    | 3. Maintenance          |
|                                | 3.3. 70 patients        |                                   | 3.1 G1-G4 = 3 (3.9%)    |
|                                | 3.4. 68 patients        | 2. Consolidation                  | 3.2 G1-G4 = 6 (8.2%)    |
|                                | 3.5. 65 patients        | Vincristine 1.5mg/m² D0 and 7     | 3.3 G1-G4 = 2 (2.9%)    |
|                                | 3.6. 65 patients        | Cytarabine 2,000mg/m² D0 and 1    | 3.4 G1-G4 = 4 (3.4%)    |
|                                | Mean age: 5.1 years     | Etoposide 200mg/m² D0 and 1       | 3.5 G1-G4 = 1 (1.5%)    |
|                                | Lymphoblastic leukemia  |                                   | 3.6 G1-G4 = 4 (6.2%)    |
|                                |                         |                                   |                         |
| Shin et al.,(24)               | 17 patients             | CHOP                              | G0 = 10 (58.84%)        |
|                                | Mean age: 38 years      | Cyclophosphamide 750mg/m² D1      | G1 = 2 (11.76%)         |
|                                | Hemophagocytic lymphohistiocytosis | Doxorubicin 50mg/m² D1             | G2 = 2 (11.76%)         |
|                                |                         | Vincristine 1.4mg/m² D1           | G3 = 3 (17.64%)         |
|                                |                         | Prednisone 40mg/m² D1-5           | G4 = 0                  |
| Blijlevens et al.,(25)         | 1. 109 patients with multiple myeloma | 1. Melphalan 200mg/m²             | 1. G0 = 10 %            |
|                                | Mean age: 56.8 years    | 2. BEAM                           | G1-G2 = 44 %            |
|                                | 2. 88 patients with non-Hodgkin's lymphoma | Carmustine 300mg/m²              | G3-G4 = 46%             |
|                                | Mean age: 50 years      | Etoposide 800mg/m²                | 2. G0 = 17%             |
|                                |                         | Cytarabine 800-1,600mg/m²         | G1-G2 = 41%             |
|                                |                         | Melphalan 140mg/m²                | G3-G4 = 42%             |
| Fadda et al.,(26)              | 231 patients before HSCT| Alkylating agents                 | 1. Melphalan             |
|                                | Mean age: 7.6 years     | 1. Melphalan                      | G9 = 20                 |
|                                |                         | 2. Busulfan                       | G1-G4 = 24              |
|                                |                         | 3. Others                         | 2. Busulfan             |
|                                |                         |                                   | G0 = 34                 |
|                                |                         |                                   | G1-G4 = 153             |
|                                |                         |                                   | 3. Others               |
|                                |                         |                                   | G0 = 42                 |
|                                |                         |                                   | G1-G4 = 64              |
| Castagna et al.,(27)           | 1. 29 patients          | 1. Melphalan                      | 1. Melphalan - G3-G4 = 17 (60%) |
|                                | Mean age: 31 years      | 2. BEAM                           | 2. BEAM - G3-G4 = 12 (60%) |
|                                | HSCT Hodgkin’s lymphoma | Carmustine 300mg/m² D1            |                         |
|                                |                         | Etoposide 800mg/m² D1-4           |                         |
|                                |                         | Cytarabine 1,600mg/m² D1-4        |                         |
|                                |                         | Melphalan 140mg/m² D1             |                         |
Table 1. Distribution of protocols used in each study and severity of oral mucositis

| Article | Sample | Protocol | Severity of mucositis |
|---------|--------|----------|-----------------------|
| Oh et al.,(28) | 43 patients | Docetaxel 70mg/m² | G1 = 1 (2.3%) |
| | | 5-FU 1200mg/m² | G2 = 1 (2.3%) |
| | | Cisplatin 40mg/m² | G3 = 0 (0) |
| Schmid et al.,(29) | 93 patients | 1. AT | 1. AT - G3-G4=4.6% |
| | | 2. Doxorubicin 60mg/m² | 2. HDCT - G3-G4=26.3% |
| | | Paclitaxel 200mg/m² | |
| | | Cyclophosphamide 2,400mg/m² | |
| | | Etoposide 2,500mg/m² | |
| Saini et al.,(30) | 716 patients | 1. 5-FU-300mg/m² IV continuous | G1 = 1 (0.2%) |
| | | 2. 5-FU 425mg/m² bolus D1-5 | G2 = 0 (0) |
| | | Mitoxantrone 45mg/m² | G3-G4 = 0 (0) |
| Kremens et al.,(31) | 20 patients | Melphalan 200mg/m² D1-5 | G3-G4 = 10 (50%) |
| | | Etoposide | |
| | | Carboxatin | |
| Lacayo et al,(32) | 38 patients | 1. DAT | 1. DAT - G3-G4 = 2 (13%) |
| | | 2. Doxorubicin 60mg/m² | 2. DAT + high doses cytarabine |
| | | Cisplatin 100mg/m² D1-7 | G3-G4 = 8 (25%) |
| | | Tioguanine 100mg/m² D1-7 | |
| | | Daunorubicin 45mg/m² D1-3 | |
| Leblond et al,(33) | 1. 48 patients | 1. FAMP | 1. FAMP - G1-G4 = 0 |
| | | 2. Fludarabine 25mg/m² D1-5 | 2. CAP - G1-G4 = 10 |
| | | 2. CAP | |
| | | Cyclophosphamide 750mg/m² D1 | |
| | | Dextran 1,000mg/m² bid D1-7 | |
| Lissoni et al,(34) | 48 patients | Epirubicin 70mg/m² | G1 = 12 |
| | | Paclitaxel 175mg/m² | G2 = 0 |
| | | Cisplatin 70mg/m² | G3 = 0 |
| Wang et al.,(35) | 16 patients | Cytarabine 3,000mg/m² bid D1-4 | G1 = 6 |
| | | Mitoxantrone 6mg/m² D1-5 | G2 = 2 |
| | | Etoposide 15mg/m² D1-7 | G3 = 5 |
| Anderson et al.,(36) | 148 patients | Cytarabine 35mg/m² D1 | G4 = 1 |
| | | Doxorubicin 35mg/m² D1 | 1. Bolus - G1-G4 = 24 (31%) |
| | | Etoposide 100mg/m² D1-5 | 2. Infusion - G1-G4 = 37 (53%) |
| | | Ifosfamide 5000mg/m² D1 | |
| Bishop et al.,(37) | 274 patients | Daunorubicin 50mg/m² D1-3 | G3-G4 = 26% |
| | | Etoposide 75mg/m² D1-7 | |
| Clavel et al,(38) | 1. 93 patients | 1. CABO | 1. G3-G4 = 24% |
| | | 2. 92 patients | 2. G3-G4 = 31 |
| | | Cisplatin 50mg/m² D4 | |
| | | Methotrexate 40mg/m² D1 and 15 | |
| | | Vincristine 7mg/m² D1, 8 and 15 | |
| | | Bleomycin 10mg/m² D1, 8 and 15 | |
| | | Vincristine 2mg/m² D1, 8 and 15 | |
| | | Methotrexate 40mg/m² D1, 8 and 15 | |
| | | Etoposide 75mg/m² D1, 8 and 15 | |
| | | Bleomycin 10mg/m² D1, 8 and 15 | |

IV: intravenous; D: day; 5-FU: 5-fluorouracil; G: grade; FOLFOX: oxaliplatin, 5-fluorouracil and leucovorin; mFOLFOX: FOLFOX with different dosage; PD: per os; FAC: 5-FU, doxorubicin and cyclophosphamide; ACP: doxorubicin, cyclophosphamide and paclitaxel; CAPOX: capecitabine and oxiplatin; CHOP: cyclophosphamide, doxorubicin, vincristine and prednisone; BEAM: carmustine, etoposide, cytarabine and melphalan; HSCT: hematopoietic stem cell transplantation; AT: doxorubicin and paclitaxel; HDCT: mitoxantrone, cyclophosphamide and etoposide; DAT: daunorubicin, cytarabine and tioguanine; FAMP: fludarabine; CABO: cisplatin, methotrexate, vincristine and bleomycin; ABO: methotrexate, vincristine and bleomycin.
developed in each protocol. The median number of subjects assessed in each article was 135 (minimum 16 and maximum 716). The mean age of participants was 43.54 years (minimum 5.2 years and maximum 65 years).

Most of the studies looked at protocols for treating carcinoma 16 (61.53%), 6 (23.07%) addressed therapy for hematological malignancies and 4 (15.4%) for hematopoietic stem cell transplantation (HSCT) (Figure 1).

In the carcinoma protocols, treatments with chemotherapeutic agents, such as 5-fluorouracil (5-FU) and platinum derivatives lead to more frequent and severe cases of OM between cycles – however, numbers varied. The use of 5-FU was strongly associated with the development of OM, according to Palappallil et al.(20) The authors demonstrated that 90% of patients developed OM after using 5-FU. Bolus administration of said agent also showed higher toxicity (19.6% of patients with OM) than continuous infusion (3.6% of patients with OM). For chemotherapeutics, such as ifosfamide and doxorubicin, greater severity of OM (53% of patients) was observed in individuals receiving continuous infusion.

Four articles (15.4%) addressed conditioning regimens for HSCT. Two of them compared the use of melphalan with the BEAM protocol (carmustine, etoposide, cytarabine and melphalan). The incidence of severe OM with melphalan was 46% in one study(25) and 60% in another.(27) The BEAM protocol also showed high incidence of severe OM in both studies (42% and 50%). This same incidence of MO with the use of melphalan was also verified by Kremens et al.,(31) (50%) and by Fadda et al.,(26) (54.4%). These two authors also found a high incidence of OM among patients receiving busulfan (81.82%).

Of the 26 articles, 6 (23.07%) reported cases of MO after treatment of hematological malignancies. During the induction phase for leukemia, no patients had OM; in the consolidation phase, 6.1% had OM; and in the maintenance phase, the highest rate was 8.2%. When assessing the chemotherapeutic agents used, we observed that 26% of patients on daunorubicin and etoposide, and 37.5% of patients on high-dose cytarabine had severe OM. Another protocol studied was cyclophosphamide, doxorubicin, vincristine and prednisone CHOP, and of the 17 patients treated, 7 (41.16%) had some degree of OM.

Of the articles reviewed, it is interesting to note that only two focused on evaluating oral toxicity resulting from the anticancer agent of choice. Most of them aimed to show the response to oncological treatment using certain chemotherapy protocols, and reporting of OM was limited to the occurrence of the condition.

The mean age of subjects was 43.54 years. This mean age reflects the fact that most studies addressed treatments for carcinoma, which is more common in adults.

In this review, many articles described the effects of chemotherapy protocols for treatment of different types of carcinoma, particularly protocols based on the use of 5-FU and platinum derivatives (cisplatin and oxyplatin). In these articles, the incidence of OM varied a great deal, but we identified that patients who received cisplatin had more severe OM.(15-17)

In the study by Lin et al.,(18) oral toxicity worsened with each subsequent cycle. Patients received three cycles of the same chemotherapy protocol, and in the first cycle, only 33.87% of patients developed OM - all cases were mild (grades 1 and 2). In the second cycle, 49.57% developed some degree of OM, and 12.18% were severe. In the third cycle, 100% of patients developed OM, of which 48.38% were grades 3 and 4. We found no evidence in the literature that OM has a cumulative effect with cycles, but in this review the increase in OM severity over the course of treatment was significant.
Palappallil et al.,(20) proposed a comparison between two different protocols for treating breast carcinoma. In both protocols, patients received cyclophosphamide and doxorubicin but, in the first protocol, 5-FU was also administered. As much as 90% of patients who received 5-FU developed some degree of OM, against only 4% of the remaining patients, which corroborates the oral toxicity of 5-FU. Administration of 5-FU was studied by Saini et al.,(30) in 716 patients with colorectal carcinoma. Only 3.6% of those who received continuous infusions of the antineoplastic drug had severe OM, whereas 19.6% of patients who received bolus infusions of 5-FU had severe OM, which implies that oral toxicity is higher when the agent is administered as a bolus. Anderson et al.,(36) also observed the mode of administration of antineoplastic agents ifosfamide and doxorubicin. Differently from Saini et al.,(30) they observed a higher incidence of OM in patients who received continuous administration (53%). Only 31% of patients who received doxorubicin and ifosfamide by bolus administration had some degree of OM.

The oral toxicity associated with conditioning regimens for HSCT is already well documented in the literature. (3,25-27,31) Despite the high incidence and the fact that oral damage caused by treatment regimens used in HSCT has prevention and treatment protocols guided by the MASCC/ISOO, there are still very few studies focusing on the effects of chemotherapeutics on the oral cavity. In this review, four articles addressing said protocols were selected. Blijlevens et al.,(25) and Castagna et al.,(27) compared the use of melphalan and the BEAM protocol as conditioning regimens for HSCT. Both found a high incidence of OM in association with both protocols, however it was slightly higher in patients submitted to conditioning with melphalan. The two papers found that, for both protocols, approximately 50% of patients developed severe OM. This demonstrates the marked oral toxicity resulting from HSCT conditioning. Kremens et al.,(31) also demonstrated a high incidence of severe MO (50%) in patients on HSCT conditioning with melphalan for Wilms tumor, despite the small sample of only 20 subjects. Still on HSCT conditioning, Fadda et al.,(26) looked at the effects of chemotherapeutics melphalan and busulfan and found that, of the patients receiving melphalan, 54.54% had some degree of OM, as described in previous studies. And as much as 81.82% of patients who received busulfan developed OM. Alkylation agents are known to form inter-filamentous bonds with DNA, i.e. the most toxic type of bonds, since DNA alkylation requires more complex repair mechanisms and may even inhibit DNA replication.

Few studies have demonstrated the relation between chemotherapy protocols used in hematological malignancies and OM severity. Abromowitch et al.,(23) demonstrated toxicity resulting from each phase of leukemia treatment. No significant oral toxicities were reported, with no patient developing OM on induction, 6.1% presenting on consolidation, and less than 10% on maintenance phases. The incidence found by those authors is too low when compared with other studies. Bishop et al.,(37) studied leukemia treatment with daunorubicin and etoposide (drugs used for induction and consolidation) and found that 26% of patients developed severe OM, i.e., a higher rate than that reported by Abromowitch et al.,(23) Among studies addressing leukemia treatments, Lacayo et al.,(32) assessed protocols with and without high-dose cytarabine for patients with acute myeloid leukemia. Patients who received high doses of cytarabine had significantly higher rates of severe OM. Wang et al.,(33) also analyzed a chemotherapy protocol based on high-dose cytarabine for treating refractory non-Hodgkin lymphoma. Although the number of patients enrolled was not very expressive (n=16), 37.5% of subjects had severe OM. This review also included another study by Shin et al.,(24) with a small number of patients, assessing cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) protocol in 17 patients with hemophagocytic lymphohistiocytosis; of those, seven patients developed some degree of OM.

CONCLUSION

Although oral mucositis affects not only the patient’s quality of life but also the course of antineoplastic treatment, few studies focused on the relation between the chemotherapy protocol and the incidence of the condition. In this review, we observed there are scarce studies assessing the relation between oral mucositis and the chemotherapy protocol used.

Through this integrative review, we further corroborate what has been frequently demonstrated in the literature: protocols for hematopoietic stem cell transplantation entail a high risk for development of oral mucositis. We also found that cytarabine, high-dose 5-FU, alkylating agents and platinum-based compounds are commonly associated with the development of oral mucositis. Therefore, when using the aforementioned protocols, attention must be paid to prevention and treatment of this condition. In addition, it is clear that further
investigations are needed concerning the oral toxicity of different drugs, to allow for more effective prevention of this condition.

REFERENCES

1. Vera-Linch M, Oster G, Ford CM, Lu J, Sonis S. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma. J Support Oncol. 2007;5(6):231-5.

2. Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001;19(8):2201-5.

3. Kwon Y. Mucositis: management. In: Sleisenger MH, Fordtran JS, eds. Gastrointestinal and Liver Disease. 8th ed. Philadelphia: WB Saunders; 2006:783-90.

4. Suresh AV, Varma PP, Sinha S, Raman R, Srinivasan M, et al. Risk-scoring system for predicting mucositis in patients of head and neck cancer receiving concurrent chemoradiotherapy (rsms-hm). J Cancer Res Ther. 2010;6(4):448-51.

5. Pico JL, Avila-Garavito A, Naccache P. Mucositis: Its Occurrence, Consequences, and Treatment in Oncology Setting. Oncologist. 1998;3(6):446-51.

6. Sonis ST. Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol. 2007;5(9 Suppl 4):3-11. Review.

7. Trucci VM, Veeck EB, Morosoli AR. Current strategies for the management of oral mucositis induced by radiotherapy or chemotherapy. Rev Odonto Cienc. 2009;24(3):309-14. Review.

8. Sonis ST. Oral mucositis. Anticancer Drugs. 2011;22(7):607-12. Review.

9. Elting LS, Cooksey C, Chambers M, Cantor SB, Manzullo E, Rubenstein J, et al. Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction. Br J Cancer. 2011;104(1):43-50.

10. Bezinelli LM, de Paula Eduardo F, da Graça Lopes RM, Biazevic MG, de Paula Eduardo C, Correa L, et al. Cost-effectiveness of the introduction of specialized oral care with laser therapy in hematopoietic stem cell transplantation. Hematol Oncol. 2014;32(1):31-9.

11. Eduardo FP, Bezinielli LM, Orsi MC, Rodrigues M, Ribeiro MS, Hamerschlag N, et al. The influence of dental care associated with laser therapy on oral mucositis during allogeneic hematopoietic cell transplant: retrospective study. einstein (São Paulo). 2011;9(2):201-6.

12. Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, McGuire DB, Migliorati C, Nicolato-Galitis O, Peterson DE, Raber-Durlacher JE, Sonis ST, Elad S; Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120(10):1453-61. Review. Erratum in: Cancer. 2015;121(8):1339.

13. Chibaudel B, Lacave R, Lefevre M, Soussan P, Antoine M, Périé S, et al. Induction therapy with cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (ETPF) in patients with resectable nonmetastatic stage III or IV squamous cell carcinoma of the oropharynx. A GERCOR phase II ECHO-07 study. Cancer Med. 2015;4(5):721-31.

14. Bano N, Najam R, Gazi F, Mateen A. Gastrointestinal adverse effects in advanced colorectal cancer patients treated with different schedules of FOLFOX. Asian Pac J Cancer Prev. 2014;15(19):8089-93.

15. Wang HM, Hsu CL, Hsieh CH, Fan KH, Lin CY, Chang JT. Concurrent chemoradiotherapy using cisplatin, tegafur, and leucovorin for advanced squamous cell carcinoma of the hypopharynx and oropharynx. Biomed J. 2014;37(3):133-40.

16. Aapro M, Andre F, Blackwell K, Clavo E, Jahanzeb M, Papazisis K, et al. Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. Ann Oncol. 2014;25(4):763-72. Review.

17. Tao CJ, Liu X, Tang LL, Mao YF, Chen L, Li WF, et al. Long-term outcome and late toxicities of simultaneous integrated boost-intensity modulated radiotherapy in pediatric and adolescent nasopharyngeal carcinoma. Chin J Cancer. 2013;32(10):525-32.

18. Lin HX, Hua YJ, Chen QY, Luo DH, Sun R, Gu F, et al. Randomized study of sinusal chromonmodulated versus flat intermittent induction chemotherapy with cisplatin and 5-fluorouracil followed by traditional radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Chin J Cancer. 2013;32(9):502-11.

19. Iwata H, Fujii H, Masuda N, Mukai H, Nishimura Y, Katsura K, et al. Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study. Breast Cancer. 2015;22(2):192-200.

20. Palapalli DS, Nair BL, Jayakumar KL, Ruvathali RT. Comparative study of the toxicity of 5-fluorouracil- Adriamycin-cyclophosphamide versus Adriamycin- cyclophosphamide followed by paclitaxel in carcinoma breast. Indian J Cancer. 2011;48(1):68-73.

21. Baird R, Biondo A, Chhayya V, McLachlan J, Karpakhasik A, Rahman S, et al. Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer and late toxicities of simultaneous integrated boost-intensity modulated radiotherapy in patients receiving high dose melphalan or BEAMing conditioning chemotherapy. European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol. 2008;26(9):1519-25.

22. Oh DY, Kwon JH, Kim TY, Kim YK, et al. Treatment Outcomes with CHOP chemotherapy in adult patients with hematopoietic lymphohistocytosis. J Korean Med Sci. 2008;23(3):439-44.

23. Ahrens T, Bornstein P, Vokurka S, Quinn B, McCann S, Easton D, et al. Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin’s lymphoma: a monocenter prospective study. Ann J Hematol. 2007;82(2):122-7.

24. Shin HJ, Chung JS, Lee JJ, Sohn SK, Choi YJ, Kim YK, et al. Treatment Outcomes with CHOP chemotherapy in adult patients with hematopoietic lymphohistocytosis. J Korean Med Sci. 2008;23(3):439-44.

25. Blijlevens N, Schwenkglenks M, Bacon P, Schippinger W, Nitsch T, Huebner G, et al. Oral mucositis and late toxicities of simultaneous integrated boost-intensity modulated radiotherapy using cisplatin, tegafur, and leucovorin for advanced colorectal carcinoma patients treated with different schedules of FOLFOX. Eur J Cancer. 2003;39(7):1339-43.

26. Kremens B, Gruhn B, Klingebiel T, Hasan C, Laws HJ, Koscielniak E, et al. Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer: results of a randomized trial. J Clin Oncol. 2005;23(3):432-40.

27. Castagna L, Magagnoli M, Balzarotti M, Sarina B, Siracusano L, Nozza A, et al. Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin’s lymphoma: a monocenter prospective study. Am J Hematol. 2007;82(2):122-7.

28. Schmid P, Schippinger W, Nitsch T, Huebner G, Heilmann V, Schultze W, et al. High-dose chemotherapy with autologous stem cell rescue in children with hematologic malignancies: a randomized controlled trial. Blood. 2008;112(7):2324-31.

29. Oh DY, Kim TY, Kwon JH, Lee JJ, Joo Y, Kim DW, et al. Docetaxel + 5-fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer. Jpn J Clin Oncol. 2005;35(7):380-5.

30. Schmid P, Schippinger W, Nitsch T, Huebner G, Heilmann V, Schultze W, et al. Frontline high-dose chemotherapy with doxorubicin plus paclitaxel in metastatic breast cancer: results of a randomized trial. J Clin Oncol. 2005;23(3):432-40.

31. Sains A, Norman AR, Cunningham D, Chau I, Hill M, Tait D, et al. Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer. 2003;88(12):1859-65.

32. Kremens B, Gruhn B, Klingebiel T, Hasan C, Laws HJ, Koscielniak E, et al. High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma. Bone Marrow Transplant. 2002;30(12):893-8.

33. Leblond V, Lévy V, Maloisel F, Cazin B, Ferrand JP, Harousseau JL, Remenier L, Porcher R, Gardembas M, Marit G, Deconinck E, Desablens B, Guilhot F, Philippe G, Stamatoullas A, Guibon D; French Cooperative Group on Chronic Lymphocytic Leukemia and Macroglobulinemia. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin- prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease. Blood. 2001;98(9):2640-4.

einstein (São Paulo). 2018;16(1):1-9
34. Lissoni A, Gabriele A, Gorga G, Turnolo S, Landoni F, Mangioni C, et al. Cisplatin, epirubicin and paclitaxel-containing chemotherapy in uterine adenocarcinoma. Ann Oncol. 1997;8(10):969-72.

35. Wang WS, Tzeng CH, Chiou TJ, Liu JH, Hsieh RK, Yen CC, et al. High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-hodgkin’s lymphoma. Jpn J Clin Oncol. 1997;27(3):154-7. Review.

36. Anderson H, Hopwood P, Prendiville J, Radford JA, Thatcher N, Ashcroft L. A randomized study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer. Br J Cancer. 1993;67(6):1385-90.

37. Bishop JF, Lowenthal RM, Joshua D, Matthews JP, Todd D, Cobcroft R, et al. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. Blood. 1990;75(1):27-32.

38. Clavel M, Cognetti F, Dodion P, Wildiers J, Rosso R, Rossi A, et al. Combination chemotherapy with methotrexate, bleomycin, and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck. Cancer. 1987;60(6):1173-7.

39. Almeida VL, Leitão A, Reina LC, Montanari CA, Donnici CL, Lopes MT. [Cancer and cell cycle-specific and cell cycle nonspecific anticancer DNA-interactive agents: an introduction]. Quim Nova. 2005;28(1):118-29. Portuguese.